Teva Pharmaceutical Industries CEO Kåre Schultz's 2019 pay falls 64% to $12M

Teva Pharmaceutical Industries reports 2019 executive compensation

By ExecPay News

Published: April 22, 2020

Teva Pharmaceutical Industries reported fiscal year 2019 executive compensation information on April 22, 2020.

In 2019, seven executives at Teva Pharmaceutical Industries received on average a compensation package of $4.5M, a 60% decrease compared to previous year.

Average pay of disclosed executives at Teva Pharmaceutical Industries

Kåre Schultz, Chief Executive Officer, received $12M in total, which decreased by 64% compared to 2018. 52% of Schultz's compensation, or $6M, was in stock awards. Schultz also received $2.9M in non-equity incentive plan, $2M in salary, as well as $727K in other compensation.

Hafrun Fridriksdottir, Executive Vice President, Global Research and Development, received a compensation package of $4.4M, which decreased by 27% compared to previous year. 43% of the compensation package, or $1.9M, was in stock awards.

Carlo de Notaristefani, Former Executive Vice President, Global Operations, earned $4.3M in 2019, a 40% decrease compared to previous year.

Michael McClellan, Chief Financial Officer, received $4.2M in 2019, which decreases by 14% compared to 2018.

Brendan O'Grady, Executive Vice President, North America Commercial, earned $3.5M in 2019.

Gianfranco Nazzi, Executive Vice President, International Markets Commercial, received $3.4M in 2019.

Eli Kalif, Chief Financial Officer, earned $21K in 2019.